Global clinical trial landscape for any disease — geographic distribution by country acros
Global clinical trial landscape for any disease — geographic distribution by country across WHO ICTRP registries (US, EU, China, India, Japan, Brazil, Africa and more), regulatory pathways, access gaps and unmet need by region. For CRO, global-pharma and advocacy agents.
150000 (raw units)
price
1
calls / 30d
1
unique payers
2026-08-20
updated
Provider
clinicalintelpulse.theaslangroupllc.com · discovered, not yet claimed by its owner
Payment (x402 accepts[])
[
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "150000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "150000",
"maxTimeoutSeconds": 604900
},
{
"scheme": "exact",
"network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
"payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
"asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
"amount": "150000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:137",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359",
"amount": "150000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:42161",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0xaf88d065e77c8cC2239327C5EDb3A432268e5831",
"amount": "150000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:480",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x79A02482A880bCe3F13E09da970dC34dB4cD24D1",
"amount": "150000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:143",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x754704Bc059F8C67012fEd69BC8A327a5aafb603",
"amount": "150000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:196",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x779ded0c9e1022225f8e0630b35a9b54be713736",
"amount": "150000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:999",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0xb88339CB7199b77E23DB6E890353E22632Ba630f",
"amount": "150000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k",
"payTo": "62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I",
"asset": "31566704",
"amount": "150000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "xrpl:0",
"payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
"asset": "XRP",
"amount": "150000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "xrpl:0",
"payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
"asset": "524C555344000000000000000000000000000000",
"amount": "0.15",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:56",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d",
"amount": "150000000000000000",
"maxTimeoutSeconds": 300
}
]Output schema
{
"bazaar": {
"info": {
"input": {
"method": "GET",
"queryParams": {
"condition": "Disease — e.g. \"Malaria\" | \"Tuberculosis\" | \"Dengue\" | \"Sickle Cell Disease\" | \"Chagas Disease\"",
"lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
"region": "global | africa | asia | europe | latin-america | middle-east | north-america (default: global)"
},
"type": "http"
},
"output": {
"example": {
"development_finance_context": "GAVI, Global Fund, UNITAID, PMI, USAID funding dominant. Wellcome Trust largest private funder.",
"global_registries_coverage": {
"anzctr_australia": "5 trials — malaria research centers in Melbourne (Burnet Institute)",
"chictr_china": "Limited malaria — primarily domestic infectious disease",
"clinical_trials_eu": "12 EU-registered trials",
"ctri_india": "18 trials — India significant manufacturer (Serum Institute)"
},
"global_trial_distribution": {
"clinicaltrials_gov_count": 312,
"estimated_non_us_registries": "200+ additional trials in WHO ICTRP member registries",
"geographic_concentration": "Sub-Saharan Africa dominates — 68% of all active malaria trials",
"most_active_countries": [
"Kenya (45 trials)",
"Uganda (38)",
"Burkina Faso (31)",
"Mali (28)",
"Tanzania (24)",
"United States (22)",
"Thailand (19)"
]
},
"opportunity_assessment": "R21 scale-up is the near-term priority. Resistance crisis in SE Asia creates urgent Phase 3 need for alternative regimens.",
"phase3_highlights": [
{
"countries": [
"Burkina Faso",
"Kenya",
"Mali",
"Tanzania"
],
"drug": "R21/Matrix-M",
"notes": "WHO prequalification received 2023. First malaria vaccine with >75% efficacy in high-transmission settings.",
"sponsor": "Serum Institute / Oxford"
}
],
"query_summary": {
"condition": "Malaria",
"region": "global"
},
"regulatory_landscape": {
"ema": "Article 58 mechanism for non-EU disease burden assessments. R21 assessed via UK MHRA.",
"fda": "Limited footprint — malaria not a US priority market; few NDA filings",
"nmpa_china": "Artemisinin derivatives approved; combination therapies standardized under WHO guidelines",
"who_prequalification": "Primary pathway for SSA deployment. RTS,S and R21 both WHO-prequalified."
},
"unmet_needs_by_region": {
"latin_america": "Vivax malaria (neglected vs. falciparum)",
"southeast_asia": "Artemisinin resistance (Pfkrelch mutations) — urgent — treatment of resistant falciparum",
"sub_saharan_africa": "Pediatric dosing, pregnancy, severe malaria, transmission blocking"
}
},
"type": "json"
}
},
"schema": {
"$schema": "https://json-schema.org/draft/2020-12/schema",
"properties": {
"input": {
"additionalProperties": false,
"properties": {
"method": {
"enum": [
"GET",
"HEAD",
"DELETE"
],
"type": "string"
},
"queryParams": {
"properties": {
"condition": {
"type": "string"
},
"lang": {
"type": "string"
},
"region": {
"type": "string"
}
},
"type": "object"
},
"type": {
"const": "http",
"type": "string"
}
},
"required": [
"type",
"method"
],
"type": "object"
},
"output": {
"properties": {
"example": {
"type": "object"
},
"type": {
"type": "string"
}
},
"required": [
"type"
],
"type": "object"
}
},
"required": [
"input"
],
"type": "object"
}
},
"builder-code": {
"info": {
"a": "bc_gxy6qn5p"
},
"schema": {
"$schema": "https://json-schema.org/draft/2020-12/schema",
"additionalProperties": false,
"properties": {
"a": {
"description": "App builder code",
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
},
"s": {
"description": "Service builder codes",
"items": {
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
},
"type": "array"
},
"w": {
"description": "Wallet builder code",
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
}
},
"type": "object"
}
}
}Use it
curl
curl "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials" # -> 402 Payment Required, accepts[] lists how to pay # retry with a PAYMENT-SIGNATURE (or PAYMENT header) once paid
JavaScript
const res = await fetch("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials");
if (res.status === 402) {
const { accepts } = await res.json();
// pay one of accepts[] via an x402 client, then retry with the payment header
}Python
import httpx
res = httpx.get("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials")
if res.status_code == 402:
accepts = res.json()["accepts"]
# pay one of accepts[] via an x402 client, then retry with the payment headerMachine-readable
Everything on this page is also available as clean JSON at /resources/4547.json, and this resource appears in /discovery/resources and /discovery/search.